Ildong, Cellivery To Co-Develop Novel Biologic For Parkinson's
This article was originally published in PharmAsia News
South Korean pharma firm Ildong and bioventure Cellivery have tied up to jointly develop an early stage, first-in-class therapy for Parkinson's disease using Cellivery's platform technology. The two hope the partnership will fundamentally change the therapeutic approach to the neurodegenerative disease.
Register for our free email digests: